Eli Lilly Acquires Adverum at $3.56 per Share, Expanding Gene Therapy Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Should l Buy LLY?
Source: PRnewswire
- Successful Tender Offer: Eli Lilly, through its wholly-owned subsidiary Flying Tigers Acquisition Corporation, proposed to acquire all outstanding shares of Adverum at $3.56 per share, with approximately 64% of shares validly tendered by the expiration date of December 8, 2025, indicating strong market support for the transaction.
- Contingent Value Rights: Each share comes with a non-tradable CVR that grants shareholders the right to receive up to $8.91 in cash upon achieving specific milestones, enhancing the appeal of the offer and potentially providing additional returns for investors.
- Strategic Integration Opportunity: This acquisition enables Lilly to expand its capabilities in gene therapy, particularly in addressing age-related conditions, which is expected to drive innovation and enhance the company's competitive position in the biotechnology sector.
- Legal and Financial Support: Lilly has engaged Ropes & Gray LLP as legal counsel, while Adverum is advised by Aquilo Partners, L.P., ensuring a smooth transaction process and reflecting the commitment of both parties to the deal's success.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.020
Low
950.00
Averages
1192
High
1500
Current: 903.020
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Stock Analysis and Outlook
- Stock Performance: Eli Lilly's stock has surged approximately 400% over the past five years, with a market cap exceeding $800 billion; despite a trailing P/E ratio near 40, its strong growth potential justifies the premium.
- Analyst Ratings: The consensus price target for Eli Lilly is slightly above $1,221, indicating about a 35% upside from current levels, with 25 out of the last 30 ratings being buy ratings, reflecting bullish sentiment among analysts regarding its future performance.
- Financial Results: In Q4 2025, Eli Lilly reported a 43% increase in sales to $19.3 billion and a 50% jump in net income to $6.6 billion, driven by the popularity of its GLP-1 drugs, Mounjaro and Zepbound, showcasing its competitive strength in the market.
- Long-Term Investment Potential: Although the stock is down 16% this year and underperforming the S&P 500, Eli Lilly's ongoing focus on growth and new drug launches positions it as an excellent long-term investment option worth considering.
See More
EMA: ALL DISCONTINUATIONS ANTICIPATED BY Q2 2027, AFTER WHICH AFFECTED INSULIN FORMULATIONS WILL BE UNAVAILABLE
Discontinuations Expected: All discontinuations are anticipated to occur before Q2 2027.
Impact on Insulin Presentations: After the discontinuations, affected insulin presentations will no longer be available.
See More
U.S. Senators Reach Agreement to Cap Insulin Prices
- Insulin Price Cap: A bipartisan group of U.S. senators has reached an agreement to cap insulin prices at $35 per month, aiming to alleviate the financial burden for nearly 30 million Americans diagnosed with diabetes, highlighting a commitment to improving public health.
- Legislative Progress: The proposal, led by Jeanne Shaheen and Susan Collins, requires support from Senate Majority Leader John Thune and President Trump, indicating the political significance and urgency of the bill in addressing healthcare costs.
- Expanded Coverage: Initially focused on insured patients, the bill now includes a pilot program allowing uninsured individuals in 10 states to access insulin at capped prices, reflecting a commitment to supporting vulnerable populations.
- Positive Market Reaction: Following the announcement, shares of major insulin producers rose in pre-market trading, with Sanofi up 2% and Eli Lilly and Novo Nordisk each gaining around 0.5%, indicating market optimism regarding the potential impact of the legislation.
See More
Bipartisan Agreement Among US Senators Aims to Limit Insulin Prices to $35 – SNY, LLY, NVO Stocks Rise in Pre-Market Trading
Proposed Legislation: A bipartisan group of U.S. senators has proposed a plan to cap insulin prices at $35 to alleviate financial burdens for millions living with diabetes, requiring support from Senate Majority Leader John Thune and President Donald Trump.
Inclusion of Uninsured Patients: The initial focus of the proposal was on insured patients, but senators John Kennedy and Raphael Warnock advocated for including uninsured individuals in the plan.
Pilot Program: The bill suggests a pilot program in 10 states to allow uninsured patients access to insulin at capped prices, addressing the high costs associated with diabetes treatment.
Pharmaceutical Cost Reforms: The legislation also aims to reduce costs by reforming pharmacy benefit manager rebate systems, although specific funding details are still being finalized.
See More
US Senators Agree to Limit Insulin Prices to $35 - Semafor
Senators Reach Agreement: U.S. senators have come to a consensus on capping insulin costs at $35.
Impact on Patients: This deal aims to alleviate the financial burden on diabetes patients who rely on insulin.
See More
Investing $400 Monthly Can Grow to $1.5 Million
- Regular Investment Advantage: Investing $400 monthly, assuming a 10% annual return, can lead to a portfolio exceeding $1.5 million after 35 years, demonstrating the immense potential of consistent small investments.
- Significant Compounding Effect: The power of compounding accelerates growth as the balance increases, highlighting the importance of ongoing investments, especially in the early stages of saving.
- Growth Fund Selection: Investing in growth-focused ETFs like the Vanguard Growth Index Fund can enhance the likelihood of achieving strong returns, even though future S&P 500 performance is uncertain.
- Diversified Portfolio: This ETF, with a low expense ratio of 0.03%, invests in 151 top growth stocks, including Nvidia and Tesla, providing excellent market exposure and helping investors achieve substantial returns over the long term.
See More
Eli Lilly Stock Analysis and Outlook
- Stock Performance: Eli Lilly's stock has surged approximately 400% over the past five years, with a market cap exceeding $800 billion; despite a trailing P/E ratio near 40, its strong growth potential justifies the premium.
- Analyst Ratings: The consensus price target for Eli Lilly is slightly above $1,221, indicating about a 35% upside from current levels, with 25 out of the last 30 ratings being buy ratings, reflecting bullish sentiment among analysts regarding its future performance.
- Financial Results: In Q4 2025, Eli Lilly reported a 43% increase in sales to $19.3 billion and a 50% jump in net income to $6.6 billion, driven by the popularity of its GLP-1 drugs, Mounjaro and Zepbound, showcasing its competitive strength in the market.
- Long-Term Investment Potential: Although the stock is down 16% this year and underperforming the S&P 500, Eli Lilly's ongoing focus on growth and new drug launches positions it as an excellent long-term investment option worth considering.
See More
EMA: ALL DISCONTINUATIONS ANTICIPATED BY Q2 2027, AFTER WHICH AFFECTED INSULIN FORMULATIONS WILL BE UNAVAILABLE
Discontinuations Expected: All discontinuations are anticipated to occur before Q2 2027.
Impact on Insulin Presentations: After the discontinuations, affected insulin presentations will no longer be available.
See More
U.S. Senators Reach Agreement to Cap Insulin Prices
- Insulin Price Cap: A bipartisan group of U.S. senators has reached an agreement to cap insulin prices at $35 per month, aiming to alleviate the financial burden for nearly 30 million Americans diagnosed with diabetes, highlighting a commitment to improving public health.
- Legislative Progress: The proposal, led by Jeanne Shaheen and Susan Collins, requires support from Senate Majority Leader John Thune and President Trump, indicating the political significance and urgency of the bill in addressing healthcare costs.
- Expanded Coverage: Initially focused on insured patients, the bill now includes a pilot program allowing uninsured individuals in 10 states to access insulin at capped prices, reflecting a commitment to supporting vulnerable populations.
- Positive Market Reaction: Following the announcement, shares of major insulin producers rose in pre-market trading, with Sanofi up 2% and Eli Lilly and Novo Nordisk each gaining around 0.5%, indicating market optimism regarding the potential impact of the legislation.
See More
Bipartisan Agreement Among US Senators Aims to Limit Insulin Prices to $35 – SNY, LLY, NVO Stocks Rise in Pre-Market Trading
Proposed Legislation: A bipartisan group of U.S. senators has proposed a plan to cap insulin prices at $35 to alleviate financial burdens for millions living with diabetes, requiring support from Senate Majority Leader John Thune and President Donald Trump.
Inclusion of Uninsured Patients: The initial focus of the proposal was on insured patients, but senators John Kennedy and Raphael Warnock advocated for including uninsured individuals in the plan.
Pilot Program: The bill suggests a pilot program in 10 states to allow uninsured patients access to insulin at capped prices, addressing the high costs associated with diabetes treatment.
Pharmaceutical Cost Reforms: The legislation also aims to reduce costs by reforming pharmacy benefit manager rebate systems, although specific funding details are still being finalized.
See More
US Senators Agree to Limit Insulin Prices to $35 - Semafor
Senators Reach Agreement: U.S. senators have come to a consensus on capping insulin costs at $35.
Impact on Patients: This deal aims to alleviate the financial burden on diabetes patients who rely on insulin.
See More
Investing $400 Monthly Can Grow to $1.5 Million
- Regular Investment Advantage: Investing $400 monthly, assuming a 10% annual return, can lead to a portfolio exceeding $1.5 million after 35 years, demonstrating the immense potential of consistent small investments.
- Significant Compounding Effect: The power of compounding accelerates growth as the balance increases, highlighting the importance of ongoing investments, especially in the early stages of saving.
- Growth Fund Selection: Investing in growth-focused ETFs like the Vanguard Growth Index Fund can enhance the likelihood of achieving strong returns, even though future S&P 500 performance is uncertain.
- Diversified Portfolio: This ETF, with a low expense ratio of 0.03%, invests in 151 top growth stocks, including Nvidia and Tesla, providing excellent market exposure and helping investors achieve substantial returns over the long term.
See More
